We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma.
- Abstract
The article informs the U.S. Food and Drug Administration (FDA) has accelerated the approval of Teclistamab-cqyv, a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It mentions the FDA granted Teclistamab Breakthrough Therapy.
- Subjects
UNITED States. Food &; Drug Administration; MULTIPLE myeloma; CD3 antigen; T cells
- Publication
Oncology Practice Management, 2023, Vol 13, Issue 1, p17
- ISSN
2164-4403
- Publication type
Article